NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lexicon Pharmaceuticals, Inc. ("Lexicon " or the "Company") (NASDAQ: LXRX). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/lxrx.
The investigation concerns whether Lexicon and certain of its officers and/or directors have violated federal securities laws.
On January 17, 2019, Lexicon announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration had “voted eight to eight on the question of whether the overall benefits of [Lexicon’s product] Zynquista (sotagliflozin) outweighed the risks to support approval.” On news of the advisory committee’s stalemate, Lexicon’s stock price fell $1.74 per share, or 22.6%, to close at $5.96 per share on January 18, 2019.
If you are aware of any facts relating to this investigation, or purchased Lexicon shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/lxrx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com